AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a study published in the July issue of The Journal of Urology.
Sakina Mohammed Mota, Ph.D., from Avenda Health, and colleagues compared physicians' performance using AI versus standard-of-care methods for tumor delineation in a multireader, multicase study. Cases were interpreted by seven urologists and three radiologists from five institutions with two to 23 years of experience. Fifty prostatectomy cases eligible for focal therapy were retrospectively assessed by each reader. Readers defined cancer contours cognitively, delineating tumor boundaries manually to encapsulate all clinically significant disease. After four or more weeks, the same cases were contoured using AI software.
The researchers found that the balanced accuracy (mean of voxel-wise sensitivity and specificity) of AI-assisted cancer contours was superior to cognitively defined and hemigland contours (84.7 percent versus 67.2 and 75.9 percent, respectively). Cancer extent was systemically underestimated by cognitively defined cancer contours, with a negative margin rate of 1.6 percent compared with 72.8 percent for AI-assisted cancer contours.
"Overall, the use of AI in cancer treatment could lead to more effective and personalized care for patients, with treatments that are better tailored to their individual needs and more successful in fighting the disease,” coauthor Wayne G. Brisbane, M.D., from the David Geffen School of Medicine in Los Angeles, said in a statement.
Several authors disclosed ties to Avenda Health.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.